FarmaKology-Viagra could be used to treat Alzheimer’s disease

Jan 03, 2022

Today's Company

Johnson & Johnson

Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the health of their skin. Those working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals use AI to discover lifesaving drugs. Imagine what the rest of our team of 134,000 people at 260 companies in more than 60 countries across the world is accomplishing. We redefine what it means to be a big company in today’s world.

News

U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

Immix Biopharma, Inc. , a biopharmaceutical company pioneering Tissue-Specific Therapeutics TM targeting oncology and immuno-dysregulated diseases, announced today that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma. IMX-110, an investigational product, is currently being evaluated in a Phase 1b/2a clinical trial.

Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib

Oncoheroes Biosciences, Inc., and Allarity Therapeutics, Inc have signed a worldwide, exclusive pediatric licensing agreement for dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib, a PARP inhibitor, both being developed by Allarity.

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

Spero Therapeutics, Inc., today announced that the U.S. Food and Drug Administration has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections, including acute pyelonephritis, caused by susceptible microorganisms. Tebipenem HBr has been granted Qualified Infectious Disease Product , Fast Track, and Priority Review designations for these cUTI indications.

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

Ascletis Pharma Inc. today announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The Company’s COVID-19 pipeline currently includes ritonavir oral tablet (100 mg), an authorized product, ASC10, an oral RNA dependent RNA polymerase (RdRp) inhibitor and ASC11, an oral 3-chymotrypsin like protease (3CLpro) inhibitor.

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the company has entered into an exclusive license agreement with AstraZeneca for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate, OV350. The company seeks to optimize and accelerate development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions.